My take on "the market" is that retail are pawns and not meant to garner much in the way of profits from investing. That is reserved for the big financial players to include banks and other corporate financial entities, stock brokerages, market makers, hedge funds, MFOs, and other very wealthy folks.
The "market" is slanted quite steeply to ensure these people make money first and if any is left over, the scraps per se, that is left for the foolish retail so they stay in the game (quite a lot like going to Vegas, right?). This can be seen by the amount of yearly profit reported by firms such as Chase, Goldman Sachs, and such that way over half their profits (read this somewhere so not positive) come from non-transparent pools. We also see major hedge funds being fed info on upcoming trading by Robinhood and such apps so the hedge funds can front run and make profits on every trade (kind of like knowing the results of a horse race before the horses leave the gate).
So it is no surprise that IPIX, having no revenue yet having substantial expenses for clinical trials would have to resort to VERY COSTLY terms to raise financing.
That is why the stock price is low and the trading so heavily off kilter to be a joke. It's just the game of the market and how it is played.
IPIX is doing a great job fighting this and it only has a chance to succeed (IMO a very good chance) because we have drugs that are mind blowing and will benefit the world tremendously.
To all new investors, IPIX share price will continue to peak and fall in dramatic rushes as MMs make their weekly profits. It will only change when IPIX secures large grants and is able to PR a successful human trial such that it is apparent Brilacidin will be able to be prescribed via an EUA (emergency use authorization). That will start money rolling in and financing issues a thing of the past.
Hang tough, for in the end IPIX looking strong.
